Navigation Links
New Data on Genmab and GlaxoSmithKline's Ofatumumab: Phase II Study,in Rheumatoid Arthritis to be Presented at EULAR

COPENHAGEN, Denmark; April 25, 2007 - Genmab A/S (CSE: GEN) announced today that the results of a Phase II study with ofatumumab (HuMax-CD20™) in patients with rheumatoid arthritis (RA) have been accepted for oral presentation at the 2007 Annual European Congress of Rheumatology (EULAR). The oral presentation, which will include new results from the double-blind, placebo controlled Phase II study with ofatumumab, along with data from the previous interim analysis, will be described by Professor Mikkel Østergaard, Department of Rheumatology, Copenhagen University Hospital on June 16, 2007. The abstract for the presentation will be available at www.eular.org in mid-May.

Genmab A/S and GlaxoSmithKline have a worldwide agreement to co-develop and commercialize ofatumumab.


About the study

A total of 226 patients with active RA who have previously failed one or more disease-modifying anti-rheumatic drugs (DMARDs) were enrolled in the Phase II study. Patients were randomized to one of 4 treatment groups (300 mg, 700 mg or 1000 mg of ofatumumab or placebo). Patients were permitted to continue therapy with stable doses of methotrexate and low dose prednisolone. ACR and EULAR responses were assessed in the primary intention-to-treat efficacy population at 24 weeks.


'"/>




Page: 1

Related medicine technology :

1. GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)
2. Genmabs HuMax-EGFr Shows Broad Potential in Cancer Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... KONG , Feb. 9, 2016 Athenex, Inc. ... Athenex as Vice President of Corporate Strategy and Business Development ... MSc, MBA has joined as Senior Director and Deputy Head of Clinical ... . Simon Pedder stated, "Athenex has ... for a while. Coupled together with their unique business model ...
(Date:2/9/2016)... 2016  The Parenteral Drug Association, Inc. (PDA), ... manufacturing sterile drug products, today announced the publication ... – With link to Comparison Spreadsheet. The ... U.S. FDA, the EU, the Pharmaceutical Inspection Convention/Scheme ... --> --> PDA,s Global Sterile ...
(Date:2/8/2016)... 2016 Respiratory Devices - Medical Devices ... Devices sector report, " Respiratory Devices - Medical ... of Respiratory Devices currently in pipeline stage. ... products with comparative analysis of the products at ... players involved in the pipeline product development. It ...
Breaking Medicine Technology:
(Date:2/9/2016)... G.A. (PRWEB) , ... February 09, 2016 , ... ... and grout cleaning and sealing company , is proud to announce that many ... their superior levels of customer service. The hard surface restoration franchises received customer ...
(Date:2/8/2016)... , ... February 08, 2016 , ... CURE Media ... has officially launched the Multiple Myeloma Heroes Awards event , which will annually ... the lives of patients with MM. The MM Heroes Awards nomination process ...
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie ... celebrates the beginning of a new charity campaign. As part of their ongoing ... Advocates (CASA). In the belief that children deserve a voice, and in the ...
(Date:2/8/2016)... New York, NY (PRWEB) , ... February 08, 2016 , ... ... handles are too much to handle, you are not alone. According to the Center ... conditions include heart disease, stroke, type 2 diabetes and certain types of cancer, some ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency Dennis ... FL area, has initiated a fundraiser for a two year old little girl ... after Christmas. To support this beautiful child who is facing life’s journey without ...
Breaking Medicine News(10 mins):